PGR and breast carcinoma: TPBCs accounted for 50.8% of HER2-positive breast cancers, while ER+PR-HER2+, ER-PR+HER2+ and ER-PR-HER2+ breast cancers accounted for 18.1%, 1.9% and 29.2%, respectively.